Trevena Investor Relations Material
Latest events
Q3 2023
Trevena
Q3 2024
7 Nov, 2024
Q2 2024
8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Trevena Inc
Access all reports
Trevena Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines targeted at central nervous system (CNS) disorders. The company's portfolio includes OLINVYK (oliceridine) injection, which is approved for use in adults to manage acute pain severe enough to require an intravenous opioid analgesic when alternative treatments are inadequate. Trevena also has several investigational drug candidates in its pipeline. The company is headquartered in Chesterbrook, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
TRVN
Country
🇺🇸 United States